Abstract
Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.
Keywords: Pharmacodynamics, Radiolabelled, Anticancer Drugs, 11C-methyl-choline, ligand-receptor, Positron Emission Tomography (PET)
Current Pharmaceutical Design
Title: Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Volume: 9 Issue: 11
Author(s): O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat. M. Price and Eric O. Aboagye
Affiliation:
Keywords: Pharmacodynamics, Radiolabelled, Anticancer Drugs, 11C-methyl-choline, ligand-receptor, Positron Emission Tomography (PET)
Abstract: Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.
Export Options
About this article
Cite this article as:
Hutchinson Clyde O., Collingridge R. David, Barthel Henryk, Price M. Pat. and Aboagye O. Eric, Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography, Current Pharmaceutical Design 2003; 9 (11) . https://dx.doi.org/10.2174/1381612033455251
DOI https://dx.doi.org/10.2174/1381612033455251 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time- and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc. has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma
MicroRNA Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies
Current Neuropharmacology Gliomagenesis and the Use of Neural Stem Cells in Brain Tumor Treatment
Anti-Cancer Agents in Medicinal Chemistry Modulation of Long Non-coding RNAs by Different Classes of Secondary Metabolites from Plants: A Mini-review on Antitumor Effects
Mini-Reviews in Medicinal Chemistry Antagonists of IAP Proteins: Novel Anti-Tumor Agents
Current Medicinal Chemistry Radiolabeled Probes Targeting G-Protein-Coupled Receptors for Personalized Medicine
Current Pharmaceutical Design 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA Using the Concept of Chous Pseudo Amino Acid Composition to Predict Enzyme Family Classes: An Approach with Support Vector Machine Based on Discrete Wavelet Transform
Protein & Peptide Letters Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Big Data for Treatment Planning: Pathways and Possibilities for Smart Healthcare Systems
Current Medical Imaging Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Membrane Interacting Peptides: A Review
Current Protein & Peptide Science Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Antidepressants and Antipsychotic Agents as Repurposable Oncological Drug Candidates
Current Medicinal Chemistry Enlightening the Mechanism of Ferroptosis in Epileptic Heart
Current Medicinal Chemistry Clinical Characteristics and Risk Factors for Bloodstream Infections in Children with Cancer: A Report from a Pediatric Hematology Oncology Unit
Cardiovascular & Hematological Agents in Medicinal Chemistry